Reverse transport

Reverse transport, or transporter reversal, is a phenomenon in which the substrates of a membrane transport protein are moved in the opposite direction to that of their typical movement by the transporter.[1][2][3][4][5] Transporter reversal typically occurs when a membrane transport protein is phosphorylated by a particular protein kinase, which is an enzyme that adds a phosphate group to proteins.[1][2]

The primary function of most neurotransmitter transporters is to facilitate neurotransmitter reuptake (i.e., the reabsorption of neurotransmitters by the cell which released them).[1][2][6] During neurotransmitter reuptake, neurotransmitter transporters will move specific types of neurotransmitters from the extracellular space into the cytosol of a neuron or glial cell.[1][2][6] When these transporters operate in reverse, they produce neurotransmitter efflux (i.e., the movement of neurotransmitters from the cytosol to the extracellular space via transporter-mediated release, as opposed to exocytotic release).[1][2] In neurons, transporter reversal facilitates the release of neurotransmitters into the synaptic cleft, resulting in a higher concentration of synaptic neurotransmitters and increased signaling through the corresponding neurotransmitter receptors.

For example, monoamine releasing agents, such as amphetamines, produce cytosolic neurotransmitter efflux (i.e., the release of monoamine neurotransmitters from neurons into the synaptic cleft via monoamine transporter-mediated release) by triggering reverse transport at vesicular monoamine transporters (specifically, VMAT1 and VMAT2) and other monoamine transporters that are located along the plasma membrane of neurons (specifically, DAT, NET, and SERT).[1][2][7] The precise mechanisms by which amphetamines and other monoamine releasing agents mediate induction of reverse transport are poorly understood.[8][9][10] Protein kinase C (PKC) and Ca2+/calmodulin-dependent protein kinase II alpha (CaMKIIα) have been shown experimentally to phosphorylate monoamine transporters and promote reverse transport after amphetamine exposure.[8][9][10]

## See also

* Active transport
* Releasing agent

## References

1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 "Kinase-dependent Regulation of Monoamine Neurotransmitter Transporters". Pharmacol. Rev. 68 (4): 888–953. October 2016. doi:10.1124/pr.115.012260. PMID 27591044.
2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 "The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity". Journal of Neurochemistry 116 (2): 164–176. January 2011. doi:10.1111/j.1471-4159.2010.07109.x. PMID 21073468.
3. ↑ "The role of zinc ions in reverse transport mediated by monoamine transporters". The Journal of Biological Chemistry 277 (24): 21505–13. 2002. doi:10.1074/jbc.M112265200. PMID 11940571.
4. ↑ "A closer look at amphetamine-induced reverse transport and trafficking of the dopamine and norepinephrine transporters". Molecular Neurobiology 39 (2): 73–80. 2009. doi:10.1007/s12035-009-8053-4. PMID 19199083.
5. ↑ "Glutamate release from platelets: exocytosis versus glutamate transporter reversal". The International Journal of Biochemistry & Cell Biology 45 (11): 2585–2595. November 2013. doi:10.1016/j.biocel.2013.08.004. PMID 23994539.
6. ↑ 6.0 6.1 "Chapter 3: Synaptic Transmission". Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (2nd ed.). New York: McGraw-Hill Medical. 2009. pp. 61–65. ISBN 9780071481274.
7. ↑ "VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse". Ann. N. Y. Acad. Sci. 1216 (1): 86–98. January 2011. doi:10.1111/j.1749-6632.2010.05906.x. PMID 21272013. Bibcode: 2011NYASA1216...86E. "VMAT2 is the CNS vesicular transporter for not only the biogenic amines DA, NE, EPI, 5-HT, and HIS, but likely also for the trace amines TYR, PEA, and thyronamine (THYR) ... [Trace aminergic] neurons in mammalian CNS would be identifiable as neurons expressing VMAT2 for storage, and the biosynthetic enzyme aromatic amino acid decarboxylase (AADC). ... AMPH release of DA from synapses requires both an action at VMAT2 to release DA to the cytoplasm and a concerted release of DA from the cytoplasm via "reverse transport" through DAT.".
8. ↑ 8.0 8.1 "Mechanisms of neurotransmitter release by amphetamines: a review". Prog Neurobiol 75 (6): 406–433. April 2005. doi:10.1016/j.pneurobio.2005.04.003. PMID 15955613.
9. ↑ 9.0 9.1 "Molecular Mechanisms of Amphetamines". Handb Exp Pharmacol. Handbook of Experimental Pharmacology 258: 265–297. 2020. doi:10.1007/164_2019_251. ISBN 978-3-030-33678-3. PMID 31286212.
10. ↑ 10.0 10.1 "Post-translational mechanisms in psychostimulant-induced neurotransmitter efflux". Pharmacological Advances in Central Nervous System Stimulants. Adv Pharmacol. 99. 2024. pp. 1–33. doi:10.1016/bs.apha.2023.10.003. ISBN 978-0-443-21933-7. https://books.google.com/books?id=2Sr6EAAAQBAJ&pg=PA1.

* v
* t
* e

Pharmacomodulation

Types|

* ♦ Enzyme: Inducer
* Inhibitor

* ♦ Ion channel: Opener
* Blocker

* ♦ Receptor: Agonist
* Partial agonist
* Antagonist
* Inverse agonist
* Positive allosteric modulator (PAM)
* Negative allosteric modulator (NAM)

* ♦ Transporter [Reuptake vs Efflux]: Enhancer (RE)
* Inhibitor (RI)
* Releaser (RA)

* ♦ Miscellaneous: Precursor
* Cofactor

Classes|

| Enzyme|

see Enzyme inhibition

|

Ion channel|

See Ion channel modulators

Receptor &
transporter|

| BA/M|

| Adrenergic|

* Adrenergic receptor agonist (α
* β (1
* 2))
* Adrenergic receptor antagonist (α (1
* 2)
* β)
* Norepinephrine reuptake inhibitor (NRI)

|

Dopaminergic|

* Dopamine receptor agonist
* Dopamine receptor antagonist
* Dopamine reuptake inhibitor (DRI)

Histaminergic|

* Histamine receptor agonist
* Histamine receptor antagonist (H1
* H2
* H3)

Serotonergic|

* Serotonin receptor agonist
* Serotonin receptor antagonist (5-HT3)
* Serotonin reuptake inhibitor (SRI)

AA|

| GABAergic|

* GABA receptor agonist
* GABA receptor antagonist
* GABA reuptake inhibitor (GRI)

|

Glutamatergic|

* Glutamate receptor agonist (AMPA)
* Glutamate receptor antagonist (NMDA)
* Glutamate reuptake inhibitor

Cholinergic|

* Acetylcholine receptor agonist (Muscarinic
* Nicotinic)
* Acetylcholine receptor antagonist (Muscarinic
* Nicotinic (Ganglionic
* Muscular))

Cannabinoidergic|

* Cannabinoid receptor agonist
* Cannabinoid receptor antagonist
* Endocannabinoid enhancer (eCBE)
* Endocannabinoid reuptake inhibitor (eCBRI)

Opioidergic|

* Opioid modulator
* Opioid receptor agonist
* Opioid receptor antagonist
* Enkephalinase inhibitor

Other|

* Adenosine reuptake inhibitor (AdoRI)
* Angiotensin II receptor antagonist
* Endothelin receptor antagonist
* NK1 receptor antagonist
* Vasopressin receptor antagonist

Miscellaneous|

* Cofactor (see Enzyme cofactors)
* Precursor (see Amino acids)

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Reverse transport. Read more

|

Retrieved from "https://handwiki.org/wiki/index.php?title=Biology:Reverse_transport&oldid=4263301"
*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template